B ($B) fluctuated 87.8% within 24 hours: Trading volume surged and leverage liquidations drove extreme volatility
Bitget Pulse2026/05/14 23:38Volatility Brief
In the past 24 hours, the price of $B surged from a low of $0.4117 to a high of $0.773, and is currently at $0.4677, representing an 87.8% price fluctuation. Trading volume increased significantly, exceeding $100 million in certain periods (such as $117.1M, $67.2M). Open interest (OI) once spiked by 2.6%, and the funding rate rose to 0.1029%.
Brief Analysis of the Cause of the Unusual Movement
- Explosive Increase in Trading Volume: Within 24 hours, trading volume soared from tens of millions of dollars to a peak of over $500 million, accompanied by rising activity on the BNB chain, driving up the price rapidly.
- Smart Money Dual-Sided Operations and Liquidations: Smart funds opened positions on both sides within the 0.387-0.687 range. The extreme OI spike (Z=4.96) triggered leveraged liquidations. After the RSI entered overbought territory, the price corrected.
Market Views and Outlook
X community sentiment is divided. Mainstream views focus on the resistance zone at $0.632-$0.774, predicting a short-term pullback to test support at $0.387 as the bottom. Analysts warn of risks from high funding rates and low volume divergence, advising caution against further long squeezes in the absence of a clear bullish breakout signal.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.